Source-grounded facts extracted from CODEXIS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CODEXIS, INC. shareholders approved Non-binding, Advisory Vote on Executive Compensation at the 2026-06-17 meeting.
“Proposal 3. Non-binding, Advisory Vote on Executive Compensation. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The voting results are as follows: Number of Votes For Against Abstain Broker Non-Votes 52,546,366 1,192,848 227,354 20,771,912”
CODEXIS, INC. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.
“Proposal 2. Ratification of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the audit committee of the Company’s board of directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows: Number of Votes For Against Abstain 74,561,400 106,175 70,905”
CODEXIS, INC. shareholders approved Election of Directors at the 2026-06-17 meeting.
“Proposal 1. Election of Directors. The Company’s stockholders elected Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi for a three-year term expiring at the 2029 annual meeting of stockholders or until their respective successors are duly elected and qualified or their earlier resignation or removal. The voting results are as follows: Number of Votes Name of Nominee For Withheld Broker Non-Votes Stephen G. Dilly, M.B.B.S., Ph.D. 47,074,970 6,891,598 20,771,912 Raymond De Vré, Ph.D. 53,369,302 597,266 20,771,912 Rahul Singhvi, Sc.D. 53,059,159 907,409 20,771,912”
CODEXIS, INC. reported the first quarter ended March 31, 2026 results: revenue $15.2 million, net income $8.7 million, or $0.10 per share, EPS $0.10 per share. Guidance reaffirmed.
“First Quarter 2026 Financial Highlights • Total revenues were $15.2 million for the first quarter of 2026 compared to $7.5 million in the first quarter of 2025. The increase was primarily due to the recognition of an additional $6.3 million in revenue from the Merck Technology Transfer agreement which we executed during the fourth quarter of 2025. • Product gross margin was 71% for the first quarter of 2026 compared to 55% in the first quarter of 2025. The increase in gross margin was largely due to a shift in sales toward more profitable products, and declines in less profitable, legacy products. • Research and Development expenses for the first quarter of 2026 were $11.4 million compared to $12.9 million in the first quarter of 2025. The decrease was primarily due to lower allocable costs, partially offset by higher employee-related costs and higher use of outside services. • Selling, General & Administrative expenses for the first quarter of 2026 were $9.8 million compared to $12.4”
CODEXIS, INC. reported fiscal year 2026 results: revenue $72 million to $76 million. Guidance initiated.
“Total revenues are expected to be in the range of $72 million to $76 million.”
CODEXIS, INC. reported fourth quarter ended December 31, 2025 results: net income The net income for the fourth quarter of 2025 was $9.6 million, or $0.11 per share.
“Total revenues increased by 81% to $38.9 million for the fourth quarter of 2025 compared to $21.5 million in the fourth quarter of 2024.”
CODEXIS, INC. reported fiscal year ended December 31, 2025 results: net income The net loss for fiscal year 2025 was $44.0 million, or $0.50 per share.
“Total revenues increased by 19% to $70.4 million for fiscal year 2025 compared to $59.3 million for fiscal year 2024.”
CODEXIS, INC. announced a restructuring with charges of approximately $3.5 million affecting ECO Synthesis platform (approximately 24%).
“benefits to impacted employees, as well as the payment of other expenses such as related tax costs, will result in the recognition of an additional expense of approximately $3.5 million. The Company anticipates this expense will be recognized in the fourth quarter of 2025 and paid primarily during the same period. The Company expects the workforce reduction to”
Byron L. Dorgan departed as director at CODEXIS, INC..
“On April 4, 2025, Byron L. Dorgan provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of his intention to retire and not to stand for reelection to the Board at the expiration of his current term at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).”
Cynthia Collins was appointed as Member of the Board, Class II Director at CODEXIS, INC..
“On March 28, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Cynthia Collins as a member of the Board as a Class II director, effective immediately.”
Christos Richards was appointed as Director at CODEXIS, INC..
“On January 14, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee (the “Nominating and Corporate Governance Committee”), appointed Christos Richards as a member of the Board as a Class II director, effective immediately.”
CODEXIS, INC.: Adopted Second Amended and Restated Bylaws to align with Delaware law, revise director nomination/disclosure requirements, and supplement stockholder meeting rules (effective 2024-11-07).
“On November 7, 2024, the Board adopted amendments to the Company’s Amended and Restated Bylaws (as so amended and restated, the “Second Amended and Restated Bylaws”), effective immediately.”
Raymond De Vré was appointed as Class I director at CODEXIS, INC..
“appointed Raymond De Vré as a member of the Board as a Class I director, effective immediately.”
Sriram Ryali departed as Chief Financial Officer at CODEXIS, INC..
“Sriram Ryali ceased to serve as the Company’s Chief Financial Officer and principal financial and accounting officer effective as of September 30, 2024.”
Sriram Ryali departed as Chief Financial Officer at CODEXIS, INC..
“On September 30, 2024, the Board appointed Georgia Erbez as the Company’s Chief Financial Officer, replacing Sriram Ryali in such role, effective September 30, 2024.”
Georgia Erbez was appointed as Chief Financial Officer at CODEXIS, INC..
“On September 30, 2024, the Board appointed Georgia Erbez as the Company’s Chief Financial Officer, replacing Sriram Ryali in such role, effective September 30, 2024.”
Alison Moore resigned as Director at CODEXIS, INC..
“In connection with her appointment as Chief Technical Officer, Dr. Moore resigned from the Board and its committees, effective as of September 30, 2024.”
Alison Moore was appointed as Chief Technical Officer at CODEXIS, INC..
“On September 30, 2024, the board of directors (the “Board”) of Codexis, Inc. (the “Company” or “Codexis”) appointed Alison Moore, Ph.D., a current member of the Board, to serve as the Company’s Chief Technical Officer.”
CODEXIS, INC. reported the first quarter ended March 31, 2024 results: revenue $17.1 million. Guidance reaffirmed.
“in the second half of 2025, ahead of an anticipated full commercial launch of the platform in 2026. First Quarter 2024 Financial Highlights • Total revenues increased by 32% to $17.1 million for first quarter 2024 compared to $13.0 million in first quarter 2023. • Product revenues increased by 14% to $9.6 million for first quarter 2024 compared to $8.4 million in”
CODEXIS, INC. engaged KPMG LLP as its auditor.
“On February 29, 2024, the Audit Committee approved the engagement of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.”
CODEXIS, INC. dismissed BDO USA, P.C. as its auditor.
“On February 29, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of Codexis, Inc. (the “Company”) dismissed BDO USA, P.C. (“BDO”) as the Company’s independent registered public accounting firm.”
Jennifer Aaker departed as Director at CODEXIS, INC..
“On February 13, 2024, Jennifer Aaker, Ph.D. provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of her intention not to stand for reelection to the Board at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).”
CODEXIS, INC. incurred term loan of up to $40.0 million with Innovatus Life Sciences Lending Fund I, LP at the greater of (i) Primate Rate and (ii) 7.50%, plus (b) 3.25% maturing 5th anniversary of the initial funding date.
“Lenders listed on Schedule 1.1 thereto, pursuant to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to $40.0 million (the “Term Loans”). Funding of the first $30.0 million tranche was completed on February 13, 2024. The Company will be eligible to draw on a second tranche of $10.0 million upon”
CODEXIS, INC. entered into Loan Agreement with Innovatus Life Sciences Lending Fund I, LP valued at up to $40.0 million (effective 2024-02-13).
“On February 13, 2024, Codexis, Inc. (the “Company”) entered into a loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (“Innovatus”) as collateral agent and the Lenders listed on Schedule 1.1 thereto, pursuant to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to $40.0 million (the “Term Loans”).”
CODEXIS, INC.: Modified definition of 'Acting in Concert' and added severability provision (effective 2024-02-08).
“On February 8, 2024, the Board of Directors (the “Board”) of Codexis, Inc., a Delaware corporation (the “Company”), approved and adopted the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), which became effective the same day, in order to modify the definition of “Acting in Concert” contained therein and include a provision regarding severability.”
CODEXIS, INC. updated its full year 2023 guidance (reaffirmed).
“On January 9, 2024, Codexis, Inc. (the “Company”) reported unaudited pro forma cash and cash equivalents of approximately $70 million as of December 31, 2023”
CODEXIS, INC. entered into A&P Acquisition Agreement with Nestlé Health Science valued at Upfront cash payment of $2.5 million, potential additional $2.5 million payment upon meeting certain (effective 2023-12-27).
“The Company will also grant Nestlé an option to enter into an agreement for the sale of assets related to amylase and protease discovered under the Collaboration Agreement (“A&P Acquisition Agreement”).”
CODEXIS, INC. terminated Strategic Collaboration Agreement with Nestlé Health Science valued at Termination of Collaboration Agreement and Development Agreement (effective 2023-12-27).
“CDX-7108 was discovered under the Strategic Collaboration Agreement between Nestlé Health Science (“Nestlé”) and the Company, dated October 12, 2017 (“Collaboration Agreement”), and was the subject of a development agreement between Nestle and the Company, dated January 1, 2020 (“Development Agreement”), pursuant to which the parties collaborated to advance the development of CDX-7108.”
CODEXIS, INC. entered into Acquisition Agreement with Nestlé Health Science valued at Upfront payment of $5.0 million, up to $15.0 million in development milestones and $25.0 million in (effective 2023-12-27).
“On December 27, 2023, the Company and Nestlé entered into an acquisition agreement (the “Acquisition Agreement”), pursuant to which the Company has agreed to assign its interests in CDX-7108 (including associated agreements and intellectual property rights) to Nestlé.”
CODEXIS, INC. announced a impairment with charges of approximately $9.2 million affecting San Carlos Facility.
“approximately $9.2 million related to the impairment and write-down of assets related to the San Carlos Facility”
CODEXIS, INC. announced a impairment with charges of approximately $0.8 million affecting Biotherapeutics.
“the Company recorded one-time, non-cash charges, including approximately $0.8 million related to goodwill impairment from the decision to discontinue investment in its Biotherapeutics programs”
CODEXIS, INC. announced a restructuring with charges of approximately $2.9 million affecting the Company (approximately 25%).
“the Company expected to record an expense of approximately $2.9 million in connection with the payment of post-employment benefits to employees impacted by the workforce reduction, as well as the payment of other expenses such as related tax costs”
CODEXIS, INC. reported financial results for for the third quarter ended September 30, 2023.
“On November 2, 2023, Codexis, Inc. announced its financial results for the quarter ended September 30, 2023.”
CODEXIS, INC.: On September 21, 2023, the Board approved and adopted amended and restated bylaws related to stockholder nominations, meeting conduct, exclusive forum provisions, and emergency bylaws (effective 2023-09-21).
“On September 21, 2023, the Board of Directors (the “Board”) of Codexis, Inc., a Delaware corporation (the “Company”), approved and adopted the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), which became effective the same day.”
CODEXIS, INC. updated its second quarter ended June 30, 2023 guidance (reaffirmed).
“Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.”
CODEXIS, INC. updated its the quarter ended June 30, 2023 guidance (reaffirmed).
“On July 20, 2023 Codexis, Inc. (the “Company”) announced certain of its preliminary unaudited financial results for the quarter ended June 30, 2023, reiterated and provided new financial guidance”
CODEXIS, INC. announced a restructuring with charges of approximately $2.9 million (approximately 25%).
“On July 20, 2023, in alignment with its enhanced strategic focus, the Company publicly announced and informed its employees that it was implementing a workforce reduction of approximately 25%. This measure was implemented in support of the Company’s organizational streamlining to focus on the continued advancement and commercialization of its Enzyme-Catalyzed Oligonucleotide (ECO) SynthesisTM platform and its highly complementary Pharmaceutical Manufacturing business. The Company expects the payment of post-employment benefits to impacted employees, as well as the payment of other expenses such as related tax costs, will result in the Company recording an expense of approximately $2.9 million.”
CODEXIS, INC.: Increased authorized shares of common stock from 100,000,000 to 200,000,000 (effective 2023-06-14).
“The increase in the authorized number of shares of the Common Stock was effected pursuant to a Certificate of Amendment of the Ninth Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 14, 2023 and was effective as of such date.”
CODEXIS, INC. shareholders approved Amendment to Codexis, Inc. 2019 Incentive Award Plan.
“Proposal No. 7 To approve an amendment to the Codexis, Inc. 2019 Incentive Award Plan: Number of Votes For Against Abstain Broker Non-Votes 27,460,337 20,804,728 89,960 6,578,228”
CODEXIS, INC. shareholders approved Codexis, Inc. 2023 Employee Stock Purchase Plan.
“Proposal No. 6 To approve the Codexis, Inc. 2023 Employee Stock Purchase Plan: Number of Votes For Against Abstain Broker Non-Votes 47,626,808 702,128 26,089 6,578,228”
CODEXIS, INC. shareholders approved Amendment to certificate of incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares.
“Proposal No. 5 To approve an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 200,000,000 shares: Number of Votes For Against Abstain 49,775,452 4,893,826 263,975”
CODEXIS, INC. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation.
“Proposal No. 4 To determine, on a non-binding, advisory basis, the frequency of future advisory votes on compensation for the Company’s named executive officers: Number of Votes For One Year Two Years Three Years Abstain Broker Non-Votes 47,842,838 43,813 399,143 69,231 6,578,228”
CODEXIS, INC. shareholders approved Advisory vote on compensation of named executive officers.
“Proposal No. 3 To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy: Number of Votes For Against Abstain Broker Non-Votes 40,824,489 7,404,355 126,181 6,578,228”
CODEXIS, INC. shareholders approved Ratification of BDO USA, LLP as independent registered public accounting firm at the 2023-12-31 meeting.
“Proposal No. 2 To ratify the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Number of Votes For Against Abstain 54,734,185 178,890 20,178”
CODEXIS, INC. shareholders approved Election of three Class I Directors.
“Proposal No. 1 To elect three Class I Directors to the Board to hold office for three-year terms expiring at the 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified or their earlier resignation or removal: Number of Votes Name of Nominee For Withheld Broker Non-Votes Stephen Dilly, M.B.B.S., Ph.D. 47,490,019 865,006 6,578,228 Alison Moore, Ph.D. 47,448,608 906,417 6,578,228 Rahul Singhvi, Sc.D. 47,811,875 543,150 6,578,228”
CODEXIS, INC. updated its fiscal year 2023 guidance (reaffirmed).
“The Company reiterated its 2023 total revenue guidance range of $63 million to $68 million, excluding enzyme sales related to PAXLOVIDTM, with adjustments to the mix of product revenues versus R&D revenues.”
CODEXIS, INC. reported first quarter ended March 31, 2023 results: revenue $13.0 million, net income $22.6 million, EPS $0.34 per share. Guidance reaffirmed.
“Total revenues for first quarter 2023 were $13.0 million compared to $14.0 million in the prior year, excluding enzyme sales related to PAXLOVIDTM of $0 and $21.3 million in each period, respectively.”
Patrick Y. Yang departed as Director at CODEXIS, INC..
“On March 29, 2023, Patrick Y. Yang, Ph.D. provided notice to the board of directors (the “Board”) of Codexis, Inc. (the “Company”) of his intention not to stand for reelection to the Board at the expiration of his current term at the 2023 annual meeting of stockholders.”
CODEXIS, INC. reported the fiscal year ended December 31, 2022 results: revenue $138.6 million.
“Total revenues for fiscal year 2022 were $138.6 million, an increase of 32% from $104.8 million the prior year.”
CODEXIS, INC. reported financial results for the fourth quarter ended December 31, 2022.
“On February 23, 2023, Codexis, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.